/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. OncLive® On Air
  2. S14 Ep83: Hot Seat: Converging Lines in the Management of RAS-Altered Cancers
S14 Ep83: Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

S14 Ep83: Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

OncLive® On Air · Jan 21, 2026

Experts discuss the rise of RAS inhibitors, detailing pivotal data in lung, pancreatic, and GYN cancers transforming this undruggable target.

CNS Penetrance Gives Adagrasib a Clinical Edge in KRAS-Mutant Lung Cancer

With efficacy and toxicity profiles being nearly identical between the first approved KRAS G12C inhibitors, intracranial activity becomes a key differentiator for clinicians, especially since a third of these lung cancer patients develop brain metastases. Adagrasib's demonstrated CNS activity gives it a slight advantage.

S14 Ep83: Hot Seat: Converging Lines in the Management of RAS-Altered Cancers thumbnail

S14 Ep83: Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

OncLive® On Air·10 months ago

Sotorasib's Confirmatory Trial Highlights a Critical PFS vs. Overall Survival Discrepancy

The confirmatory Code Break 200 study for sotorasib demonstrated a statistically significant improvement in progression-free survival (PFS) over docetaxel. However, it failed to show a similar benefit in overall survival (OS), a critical distinction for oncologists weighing long-term patient outcomes.

S14 Ep83: Hot Seat: Converging Lines in the Management of RAS-Altered Cancers thumbnail

S14 Ep83: Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

OncLive® On Air·10 months ago

High Toxicity of New Ovarian Cancer Combo Creates Opportunity for Better-Tolerated KRAS Inhibitors

While the avutometanib/defactinib combination is newly approved for KRAS-mutated ovarian cancer, its significant toxicity profile—causing up to a third of patients to stop treatment—creates a clear clinical need for agents like specific KRAS inhibitors that may offer similar efficacy with better tolerability.

S14 Ep83: Hot Seat: Converging Lines in the Management of RAS-Altered Cancers thumbnail

S14 Ep83: Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

OncLive® On Air·10 months ago

Divarasib's Trial Design Pits It Directly Against Sotorasib, Signaling a Mature KRAS Inhibitor Market

Instead of a traditional chemotherapy comparison, Divarasib's registrational study is a head-to-head trial against approved KRAS G12C inhibitors. This trial design reflects a strategic shift towards proving superiority within a new drug class, not just efficacy against older standards of care.

S14 Ep83: Hot Seat: Converging Lines in the Management of RAS-Altered Cancers thumbnail

S14 Ep83: Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

OncLive® On Air·10 months ago

Pan-RAS Inhibitor Direxonrasib Achieves Lung Cancer-Like Responses in Pancreatic Cancer

Direxonrasib is showing unprecedented response rates (e.g., 47% in frontline) for metastatic pancreatic cancer, a historically difficult-to-treat disease. This high performance prompts comparisons to the targeted therapy successes seen in lung cancer, signaling a potential paradigm shift in treatment expectations for PDAC.

S14 Ep83: Hot Seat: Converging Lines in the Management of RAS-Altered Cancers thumbnail

S14 Ep83: Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

OncLive® On Air·10 months ago

KRAS G12D Inhibitor Zoldanrasib Targets Younger, Never-Smoker Lung Cancer Patients

The KRAS G12D mutation, unlike the more common G12C, often occurs in younger, never-smoking lung cancer patients who previously lacked targeted therapy options. The high response rate (61%) and good tolerability of the G12D inhibitor Zoldanrasib could fill a significant unmet need in this specific demographic.

S14 Ep83: Hot Seat: Converging Lines in the Management of RAS-Altered Cancers thumbnail

S14 Ep83: Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

OncLive® On Air·10 months ago